Humana Inc. found using ticker (HUM) now have 25 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 534 and 400 calculating the mean target price we have 454.24. Now with the previous closing price of 444.31 this indicates there is a potential upside of 2.2%. The 50 day MA is 414.5 and the 200 day MA is 397.34. The market capitalisation for the company is $57,565m. Company Website: http://www.humana.com
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2019, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.